What is personalized medicine?

Personalized medicine programs have been developed to characterize the population that responds to a certain drug treatment regarding gene or protein expressions. ImaBiotech has a great experience in finding new biomarkers and monitoring targeted biomarkers, especially in oncology. Through Multimaging, ImaBiotech proposes different programs to identify, quantify and localize biomarkers related to gene mutations. The team has developed a huge expertise in metabolomics, lipidomics and proteomics with more than +100 publications in these fields.

What can be achieved?

Evaluation of targeted biomarker (localization, concentration, morphology) for preclinical and clinical samples

Identify new biomarkers in proteomics, metabolomics or lipidomics

Classification of patients based on tissue biomarker (intensity or morphology parameters)


We have experienced in biomarker research

  • A team of statistician and bioinformatician with expertise in classification, computer vision and statistical tools
  • Number of scientist coming from the most recognized Lab, with expertise in proteomics, metabolomics and lipidomics
  • State-of-the-art platform with high resolution instruments
  • Statistical analysis based on intensity scale, absolute concentration or Morphometry analysis (Image feature analysis)
  • From statistical analysis (multivariate, PCA, T-Test, ANOVA-test)
  • Data base of 2500 identified molecules from rodent animals

Examples of biomarkers of efficacy

  • Immune-oncology IDO model (Tryptophan, Kynurenine pathway)
  • IDH1 and IDH2 models (2-hydroxy-glutarate)
  • CD73 – GCN2 activity (Adenosine and Inosine markers)
  • Glycolysis pathway (Glucose, Fructose markers)
  • Regulatory T-Cell activity
  • T-cell activity
  • Amino acids
  • Krebs cycle
  • Phenylalanine Biosynthesis
  • Arginine Biosynthesis
  • Neurotransmitters
  • 450 Lipids (FA, TG, DG, gangliosides, etc…)
  • Sterols
  • Histone Acetylation

Contact us

I accept to receive the newsletter